PPARG and thromboangiitis obliterans: These studies also suggest that potential therapies for TAO may be directed towards inhibition of the adipogenic pathway through the use of a PPAR-γ inhibitor, although the detrimental metabolic effects should be considered, and that PPAR-γ expression could potentially be utilized as a marker for TAO disease activity [7,8].